"At Minnesota Oncology, we are dedicated to providing compassionate care for various types of cancer and blood disorders in 12 convenient Twin Cities metro locations as well as several satellite locations. Our mission is to combine the strength of hope with the power of science, one patient at a time."

During the past decade, Minnesota Oncology-Minneapolis conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minnesota Oncology-Minneapolis" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Agendia" with 1 trials sponsored, "Hutchison Medipharma Limited" with 1 trials sponsored, "Mirati Therapeutics Inc." with 1 trials sponsored and "NSABP Foundation Inc" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minnesota Oncology-Minneapolis" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Minnesota Oncology-Minneapolis" are "Bladder Cancer" (2 trials), "Breast Cancer" (2 trials), "Metastatic Colorectal Cancer" (2 trials), "Adult Solid Tumor" (1 trials) and "Advanced Cancer" (1 trials). Many other conditions were trialed in "Minnesota Oncology-Minneapolis" in a lesser frequency.

Most popular intervention types in "Minnesota Oncology-Minneapolis" are "Drug" (7 trials), "Diagnostic Test" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Pembrolizumab" (2 trials), "Pemetrexed" (2 trials), "Afatinib" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Minnesota Oncology-Minneapolis" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Minnesota Oncology-Minneapolis". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Minnesota Oncology-Minneapolis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Minnesota Oncology-Minneapolis, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".